	US 12,130,294 B2
	Quantification of biomarkers present in physiological samples
Edward Kevin Hrusovsky, Hopkinton, MA (US); David Wilson, Boxborough, MA (US); Dandan Shan, Acton, MA (US); Lei Chang, Winchester, MA (US); Linan Song, Waltham, MA (US); Andreas Jeromin, Alachua, FL (US); Carmen Ioana Tobos, Farmington Hills, MI (US); and Purvish Prahlad Patel, Medford, MA (US)
Assigned to QUANTERIX CORPORATION, Lexington, MA (US)
Appl. No. 17/046,119
Filed by QUANTERIX CORPORATION, Lexington, MA (US)
PCT Filed Apr. 9, 2019, PCT No. PCT/US2019/026640 § 371(c)(1), (2) Date Oct. 8, 2020, PCT Pub. No. WO2019/199869, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/789,067, filed on Jan. 7, 2019.
Claims priority of provisional application 62/655,738, filed on Apr. 10, 2018.
Prior Publication US 2021/0102959 A1, Apr. 8, 2021
Int. Cl. G01N 33/68 (2006.01); A61B 5/00 (2006.01); G01N 1/38 (2006.01); G01N 33/58 (2006.01)

CPC G01N 33/6896 (2013.01) [A61B 5/0071 (2013.01); A61B 5/0075 (2013.01); A61B 5/0082 (2013.01); A61B 5/4064 (2013.01); G01N 1/38 (2013.01); G01N 33/582 (2013.01); G01N 2001/386 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/285 (2013.01)]

16 Claims

1. A kit, comprising:

i) a plurality of capture agents comprising:

a) a first capture agent comprising a first antibody capable of specifically binding tau protein (Tau); and

b) a second capture agent comprising a second antibody capable of specifically binding neurofilament light chain (NF-L);

ii) a plurality of detection agents comprising:

a) a first detection agent comprising a first antibody capable of specifically binding the Tau; and

b) a second detection agent comprising a second antibody capable of specifically binding the NF-L;

iii) a sample diluent comprising human IgG at a concentration of between 1 mg/mL and 10 mg/mL; and

iv) a plurality of calibration solutions comprising a plurality of predetermined concentrations of the Tau and the NF-L.